Previous close | 2.8900 |
Open | 2.9700 |
Bid | 0.0000 x 21500 |
Ask | 0.0000 x 1200 |
Day's range | 2.8900 - 3.3800 |
52-week range | 2.4900 - 10.3300 |
Volume | |
Avg. volume | 2,597,116 |
Market cap | 422.33M |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 09 Nov 2012 |
1y target est | N/A |
We've seen this movie before only to watch dip-buyers get fleeced — but money managers are now warming to the idea of a material bounce in stocks.
Biotech stocks have put plenty of investors on the road to riches in recent years. Or we can refer to a smaller player like Novavax, which soared 2,700% in one year on optimism about its coronavirus vaccine program. Investors already know Moderna (NASDAQ: MRNA) for its blockbuster coronavirus vaccine, and that's why it might be overlooked right now.
Since the end of the Great Recession 13 years ago, growth stocks have dominated. According to consensus revenue estimates from Wall Street, the following three companies should be among the fastest-growing stocks on the planet through 2026. Perhaps it's no surprise that one of the hottest initial public offerings of 2021, electric-vehicle (EV) manufacturer Rivian Automotive (NASDAQ: RIVN), is expected to be one of the stock market's fastest-growing stocks over the next five years.